IL319342A - Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide - Google Patents

Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide

Info

Publication number
IL319342A
IL319342A IL319342A IL31934225A IL319342A IL 319342 A IL319342 A IL 319342A IL 319342 A IL319342 A IL 319342A IL 31934225 A IL31934225 A IL 31934225A IL 319342 A IL319342 A IL 319342A
Authority
IL
Israel
Prior art keywords
cancer
cocrystalline form
cocrystalline
urothelial
bladder cancer
Prior art date
Application number
IL319342A
Other languages
English (en)
Hebrew (he)
Inventor
David Andrew Coates
Lori Raquel Hilden
Gislaine Kuminek
Jeffrey A Peterson
Original Assignee
Lilly Co Eli
David Andrew Coates
Lori Raquel Hilden
Gislaine Kuminek
Jeffrey A Peterson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, David Andrew Coates, Lori Raquel Hilden, Gislaine Kuminek, Jeffrey A Peterson filed Critical Lilly Co Eli
Publication of IL319342A publication Critical patent/IL319342A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL319342A 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide IL319342A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
IL319342A true IL319342A (en) 2025-05-01

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319342A IL319342A (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyl-triazol-1-yl]piperidine-1-caridine-1-caridine and nicotinamide

Country Status (18)

Country Link
US (1) US12662483B2 (cg-RX-API-DMAC7.html)
EP (1) EP4584270A1 (cg-RX-API-DMAC7.html)
JP (2) JP7541606B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250057022A (cg-RX-API-DMAC7.html)
CN (1) CN120187720A (cg-RX-API-DMAC7.html)
AR (1) AR130417A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023338199B2 (cg-RX-API-DMAC7.html)
CA (1) CA3266872A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025002467A2 (cg-RX-API-DMAC7.html)
CR (1) CR20250077A (cg-RX-API-DMAC7.html)
DO (1) DOP2025000054A (cg-RX-API-DMAC7.html)
IL (1) IL319342A (cg-RX-API-DMAC7.html)
JO (1) JOP20250053A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002687A (cg-RX-API-DMAC7.html)
PE (1) PE20251400A1 (cg-RX-API-DMAC7.html)
TW (1) TWI862146B (cg-RX-API-DMAC7.html)
WO (1) WO2024054814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途
WO2026084690A1 (en) * 2024-10-14 2026-04-23 Eli Lilly And Company Fgfr3 inhibitor dosing regimens for use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163790B2 (en) * 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
DOP2025000054A (es) 2025-03-31
AU2023338199A1 (en) 2025-03-20
EP4584270A1 (en) 2025-07-16
JP2024037713A (ja) 2024-03-19
AU2023338199B2 (en) 2026-07-16
US12662483B2 (en) 2026-06-23
AR130417A1 (es) 2024-12-04
CL2025000596A1 (es) 2025-04-25
JP2024153948A (ja) 2024-10-29
CA3266872A1 (en) 2024-03-14
WO2024054814A1 (en) 2024-03-14
CR20250077A (es) 2025-04-02
JOP20250053A1 (ar) 2025-03-06
CO2025002467A2 (es) 2025-03-17
US20240116932A1 (en) 2024-04-11
TW202428260A (zh) 2024-07-16
KR20250057022A (ko) 2025-04-28
TWI862146B (zh) 2024-11-11
CN120187720A (zh) 2025-06-20
MX2025002687A (es) 2025-04-02
JP7541606B2 (ja) 2024-08-28
PE20251400A1 (es) 2025-05-22

Similar Documents

Publication Publication Date Title
JP2024037713A5 (cg-RX-API-DMAC7.html)
DK2716633T3 (en) QUINAZOLINE DERIVATIVE AS A TYROSIN-KINASE INHIBITOR, PROCEDURE FOR PREPARING IT AND USING THEREOF
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
RU2010142396A (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1-н-бензимидазол-2-ил] хинолин-2(1н)она
CN102516263A (zh) 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
RU2012144420A (ru) Новые способы направленного воздействия на раковые стволовые клетки
WO2024214019A1 (en) Tetracyclic compounds as smarca2 and/or smarca4 degraders
RU2007141198A (ru) Кристаллическая форма малеата азенапина
US20150291532A1 (en) Amorphous form of quinoline derivative, and method for producing same
EP4514466A1 (en) Inhibitors of rock2
Wang et al. Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor
Gao et al. Complexation with aromatic carboxylic acids expands the solid-state landscape of berberine
AU2021323828A1 (en) Quinoline compounds and compositions for inhibiting EZH2
PE20251400A1 (es) Derivados de co-cristales de 4-[4-[3-cloro-4-[1- (2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con acido galico y amida nicotinica
EP1549647B1 (de) Substituierte c-imidazo¬1,2-a|pyridin-3-yl-methylamine
CN104860922A (zh) 作为间变性淋巴瘤激酶抑制剂的嘧啶衍生物
CN108084177B (zh) 一种小檗碱9-位吡唑衍生物及其制备和应用
EP1549650B1 (de) Substituierte c-imidazo[1,2-a]lpyridin-3yl-methylamine
US10196344B2 (en) Glaucocalyxin a derivative and preparation method and application thereof
CN102731519B (zh) 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药
CN105439913B (zh) 一种吉马酮衍生物及其制备方法和应用
WO2019141549A1 (en) 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
US11111234B2 (en) Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
CN103588776A (zh) 葱莲中具有抗肿瘤作用的化合物及其分离制备方法和应用
CN116554111B (zh) 一种厄洛替尼共无定形物及其制备方法与应用